Previous 10 | Next 10 |
2024-02-14 08:30:24 ET Summary Omeros has suffered from underperformance of its Narsoplimab lead therapy. OMIDRIA, Omeros' sole approved therapy, has provided significant cash infusions as Omeros has sold it off piecemeal. Well situated for liquidity over the next two years, O...
2024-02-07 09:34:32 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips In general, high- growth stocks and sleeper stocks under $15 are associated with valuation concerns. Let’s forget inflated giants and overhyped darlings. Today, the article reveals t...
– Expands DRI royalty deal on U.S. net sales of OMIDRIA – – Expanded deal brings Omeros $115 million upfront payment and opportunity for additional $55 million in sales-based milestones – Omeros Corporation (Nasdaq: OMER) today announced the sale to D...
2024-01-23 09:59:59 ET More on Health Care Select Sector SPDR Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Investors were most bullish on H...
2023-12-24 13:08:45 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips While the concept of short-squeeze stocks has been all the rage throughout most of the pandemic-disruption cycle, we may have been doing this all wrong. Rather, it’s time to address this...
2023-11-27 01:18:10 ET Summary Omeros Corporation focuses on small-molecule and antibody drugs for common disorders and rare diseases. The company has prioritized the resubmission of its BLA for Narsoplimab for TA-TMA treatment and is advancing Phase-3 clinical trials for MASP-3 i...
2023-11-17 05:55:00 ET Summary Biotech sector faces challenges including higher interest rates, inflation, regulatory pressures, and a post-COVID slump. Short interest remains high for some pharmaceutical companies, indicating bearish sentiment. Exchange-traded funds in the bi...
2023-11-10 10:32:09 ET Omeros Corporation (OMER) Q3 2023 Earnings Conference Call November 09, 2023 04:30 PM ET Company Participants Jennifer Williams - Investor Relations Greg Demopulos - Chairman & Chief Executive Officer Mike Jacobsen - Chief Accounting Of...
2023-11-09 16:27:39 ET More on Omeros Omeros: Where Medical Hopes Tangle With Fiscal Ropes Omeros: Betting Big On Narsoplimab, We Are Still A Buyer Omeros Q3 2023 Earnings Preview Omeros stock plunges 48% on failed Phase 3 study for narsoplimab Seekin...
– Conference Call Today at 1:30 p.m. ET Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic dis...
News, Short Squeeze, Breakout and More Instantly...
– Conference Call Today at 4:30 p.m. ET Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic dis...
The CNN Money Fear and Greed index showed a slight decline in overall market sentiment, but it remained in the "Greed" zone on Thursday. ...
GD Culture Group Limited (GDC) is expected to report for Q4 2023 Citizens Inc. Class A ($1.00 Par) (CIA) is expected to report for quarter end 2023-12-31 Escalade Incorporated (ESCA) is expected to report for Q4 2023 Lendway Inc. (LDWY) is expected to report for quarter end 2023-12-31...